These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 34862313)

  • 1. Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series.
    Assawasaksakul T; Sathitratanacheewin S; Vichaiwattana P; Wanlapakorn N; Poovorawan Y; Kittanamongkolchai W
    RMD Open; 2021 Dec; 7(3):. PubMed ID: 34862313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study.
    Hua Q; Zhang H; Yao P; Xu N; Sun Y; Lu H; Xu F; Liao Y; Yang J; Mao H; Zhang Y; Zhu H; Hu X; Lv H; Jiang J
    Front Immunol; 2022; 13():939311. PubMed ID: 36032136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus.
    Yuki EFN; Borba EF; Pasoto SG; Seguro LP; Lopes M; Saad CGS; Medeiros-Ribeiro AC; Silva CA; de Andrade DCO; Kupa LVK; Betancourt L; Bertoglio I; Valim J; Hoff C; Formiga FFC; Pedrosa T; Kallas EG; Aikawa NE; Bonfa E
    Arthritis Care Res (Hoboken); 2022 Apr; 74(4):562-571. PubMed ID: 34806342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Immunogenicity and Safety of Inactivated, Adenovirus-Vectored, and Heterologous Adenovirus-Vectored/mRNA Vaccines in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Prospective Cohort Study.
    Assawasaksakul T; Lertussavavivat T; Sathitratanacheewin S; Oudomying N; Vichaiwattana P; Wanlapakorn N; Poovorawan Y; Avihingsanon Y; Assawasaksakul N; Buranapraditkun S; Kittanamongkolchai W
    Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine.
    Yong X; Liu J; Zeng Y; Nie J; Cui X; Wang T; Wang Y; Chen Y; Kang W; Yang Z; Liu Y
    Hum Vaccin Immunother; 2023 Dec; 19(3):2267869. PubMed ID: 37854013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attitudes towards and safety of the SARS-CoV-2 inactivated vaccines in 188 patients with systemic lupus erythematosus: a post-vaccination cross-sectional survey.
    Tang Q; Li F; Tian J; Kang J; He J
    Clin Exp Med; 2023 Jun; 23(2):457-463. PubMed ID: 35612692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.
    Zhang R; Leung KY; Liu D; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF
    mSphere; 2022 Apr; 7(2):e0091521. PubMed ID: 35285250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis.
    Assawasaksakul T; Sathitratanacheewin S; Vichaiwattana P; Wanlapakorn N; Poovorawan Y; Avihingsanon Y; Assawasaksakul N; Kittanamongkolchai W
    Lupus Sci Med; 2022 Jul; 9(1):. PubMed ID: 35902168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of the BBIBP-CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort.
    Zamani B; Moradi Hasan-Abad A; Piroozmand A; Dehghani M; Arfaatabar M; Motedayyen H
    Immun Inflamm Dis; 2023 May; 11(5):e858. PubMed ID: 37249277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults.
    Zhang Y; Yang Y; Qiao N; Wang X; Ding L; Zhu X; Liang Y; Han Z; Liu F; Zhang X; Yang X
    Front Med; 2022 Feb; 16(1):93-101. PubMed ID: 35122211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19.
    Zhao W; Chen W; Li J; Chen M; Li Q; Lv M; Zhou S; Bai S; Wang Y; Zhang L; Zhang P; Wang J; Zheng Q; Wu J
    mBio; 2022 Jun; 13(3):e0018122. PubMed ID: 35475648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients.
    Gualano B; Saad CGS; Sieczkowska SM; Lemes ÍR; da Silva RP; Pinto AJ; Mazzolani BC; Smaira FI; Gil S; Oliveira-Junior G; Aikawa NE; Medeiros-Ribeiro AC; Silva CA; Yuki EFN; Pasoto SG; Pereira RMR; Shinjo SK; Andrade DCO; Sampaio-Barros PD; Roschel H; Bonfa E
    J Appl Physiol (1985); 2022 Mar; 132(3):682-688. PubMed ID: 35142560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies.
    Morales-Núñez JJ; Muñoz-Valle JF; Machado-Sulbarán AC; Díaz-Pérez SA; Torres-Hernández PC; Panduro-Espinoza BV; Gallegos-Díaz de Leon JA; Munguía-Ramirez CD; Hernández-Bello J
    Immunol Lett; 2022 Dec; 251-252():20-28. PubMed ID: 36279685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2.
    Shinjo SK; de Souza FHC; Borges IBP; Dos Santos AM; Miossi R; Misse RG; Medeiros-Ribeiro AC; Saad CGS; Yuki EFN; Pasoto SG; Kupa LVK; Ceneviva C; Seraphim JC; Pedrosa TN; Vendramini MBG; Silva CA; Aikawa NE; Bonfá E
    Rheumatology (Oxford); 2022 Aug; 61(8):3351-3361. PubMed ID: 34664616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus.
    So H; Li T; Chan V; Tam LS; Chan PK
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221089586. PubMed ID: 35464809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19].
    Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P
    Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2.
    Jin L; Li Z; Zhang X; Li J; Zhu F
    Hum Vaccin Immunother; 2022 Nov; 18(6):2096970. PubMed ID: 35878789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen.
    Keskin AU; Bolukcu S; Ciragil P; Topkaya AE
    J Med Virol; 2022 Jan; 94(1):39-41. PubMed ID: 34536028
    [No Abstract]   [Full Text] [Related]  

  • 19. Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity.
    Pasoto SG; Halpern ASR; Guedes LKN; Ribeiro ACM; Yuki ENF; Saad CGS; da Silva CAA; de Vinci Kanda Kupa L; Villamarín LEB; de Oliveira Martins VA; Martins CCMF; Deveza GBH; Leon EP; Bueno C; Pedrosa TN; Santos REB; Soares R; Aikawa NE; Bonfa E
    Clin Rheumatol; 2022 Jul; 41(7):2079-2089. PubMed ID: 35306594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 4 clinical trials in the era of the Coronavirus Disease (COVID-19) pandemic and their importance to optimize the COVID-19 vaccination.
    Ralise AEG; Camargo TM; Marson FAL
    Hum Vaccin Immunother; 2023 Aug; 19(2):2234784. PubMed ID: 37449956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.